Additionally, the combination of uliledlimab (anti-CD73) and toripalimab (anti-PD-1) has demonstrated increased ORR in NSCLC cohorts, with ongoing trials [NCT04322006] (Table 1). Here, PDCD1 is linked to non-small cell lung carcinoma.